[18F]TFB PET/CT与治疗剂量[131I]碘SPECT/CT及[18F]FDG PET/CT在复发性分化型甲状腺癌中的诊断效能比较
回顾性纳入26例接受高活度[131I]碘治疗的分化型甲状腺癌患者,比较治疗前[18F]TFB PET/CT与治疗后[131I]碘全身显像及SPECT/CT、以及[18F]FDG PET/CT对复发病灶的检出。共识别62个可疑病灶,其中[131I]碘阳性30个、[18F]TFB阳性32个、[18F]FDG阳性52个。[18F]TFB PET/CT可能有助于预测复发病灶[131I]碘扫描阳性,从而帮助筛选[131I]碘治疗患者。
要点
- 治疗前[18F]TFB PET/CT可能有助于预测复发性分化型甲状腺癌病灶在[131I]碘扫描上的阳性。
- 共62个可疑病灶中,[131I]碘阳性30个、[18F]TFB阳性32个、[18F]FDG阳性52个。
- 病灶[18F]TFB摄取与[18F]FDG摄取呈显著负相关,可能作为去分化标志物。
核心结论
- 治疗前[18F]TFB PET/CT可能有助于预测复发性分化型甲状腺癌病灶在[131I]碘扫描上的阳性,从而可能帮助筛选适合[131I]碘治疗的患者。
- 未来需要前瞻性试验来指导碘治疗。
- 病灶[18F]TFB摄取似乎与[18F]FDG摄取呈负相关,因此可能作为分化型甲状腺癌的去分化标志物。
研究设计与样本
- 回顾性纳入2020年5月至2022年11月间接受高活度放射性[131I]碘治疗(范围5.00-10.23 GBq)的26例患者。
- 治疗前所有患者接受[18F]TFB PET/CT,注射中位321 MBq后40分钟显像;23例在90分钟追加扫描以研究示踪剂动力学。
- 治疗后中位3.8天行[131I]碘治疗性全身显像及SPECT/CT;25例另行[18F]FDG PET。
- 由两名经验丰富的核医学科医师对所有影像模态进行共识评估。
主要发现
- 共识别62个可疑病灶,其中[131I]碘阳性30个、[18F]TFB阳性32个、[18F]FDG阳性52个。
- 30个[131I]碘阳性病灶中3个回顾性判定为假阳性碘摄取。
- 40分钟与90分钟时间点的肿瘤/本底比值高度相关,例如肌肉肿瘤/本底比值的Pearson相关系数为0.91(P < 0.001,n = 49)。
- [18F]TFB摄取与[18F]FDG摄取呈显著负相关(Pearson相关系数-0.26,P = 0.041,n = 62)。
临床怎么用
- 作者认为,治疗前[18F]TFB PET/CT可能有助于预测复发性分化型甲状腺癌病灶在[131I]碘扫描上的阳性,并可能帮助筛选[131I]碘治疗患者。
- 作者认为,病灶[18F]TFB摄取似乎与[18F]FDG摄取呈负相关,可能作为去分化标志物;未来需要前瞻性试验来指导碘治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
[18F]tetrafluoroborate ([18F]TFB) is an emerging PET tracer with excellent properties for human sodium iodide symporter (NIS)-based imaging in patients with differentiated thyroid cancer (DTC). The aim of this study was to compare [18F]TFB PET with high-activity posttherapeutic [131I]iodine whole-body scintigraphy and SPECT/CT in recurrent DTC and with [18F]FDG PET/CT in suspected dedifferentiation. Methods: Twenty-six patients treated with high-activity radioactive [131I]iodine therapy (range, 5.00-10.23 GBq) between May 2020 and November 2022 were retrospectively included. Thyroid-stimulating hormone was stimulated by 2 injections of recombinant thyroid-stimulating hormone (0.9 mg) 48 and 24 h before therapy. Before treatment, all patients underwent [18F]TFB PET/CT 40 min after injection of a median of 321 MBq of [18F]TFB. To study tracer kinetics in DTC lesions, 23 patients received an additional scan at 90 min. [131I]iodine therapeutic whole-body scintigraphy and SPECT/CT were performed at a median of 3.8 d after treatment. Twenty-five patients underwent additional [18F]FDG PET. Two experienced nuclear medicine physicians evaluated all imaging modalities in consensus. Results: A total of 62 suspected lesions were identified; of these, 30 lesions were [131I]iodine positive, 32 lesions were [18F]TFB positive, and 52 were [18F]FDG positive. Three of the 30 [131I]iodine-positive lesions were retrospectively rated as false-positive iodide uptake. Tumor-to-background ratio measurements at the 40- and 90-min time points were closely correlated (e.g., for the tumor-to-background ratio for muscle, the Pearson correlation coefficient was 0.91; P < 0.001; n = 49). We found a significant negative correlation between [18F]TFB uptake and [18F]FDG uptake as a potential marker for dedifferentiation (Pearson correlation coefficient, -0.26; P = 0.041; n = 62). Conclusion: Pretherapeutic [18F]TFB PET/CT may help to predict the positivity of recurrent DTC lesions on [131I]iodine scans. Therefore, it may help in the selection of patients for [131I]iodine therapy. Future prospective trials for iodine therapy guidance are warranted. Lesion [18F]TFB uptake seems to be inversely correlated with [18F]FDG uptake and therefore might serve as a dedifferentiation marker in DTC.
引用
- Ventura D, Dittmann M, Büther F, et al. Diagnostic Performance of [18F]TFB PET/CT Compared with Therapeutic Activity [131I]Iodine SPECT/CT and [18F]FDG PET/CT in Recurrent Differentiated Thyroid Carcinoma. J Nucl Med. 2024. PMID: 38164565. doi:10.2967/jnumed.123.266513
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。